CoChat

A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia

Open access
Marín-Ramos, Nagore I., Balabasquer, Moisés, Ortega-Nogales, Francisco J., Torrecillas, Iván R., Gil-Ordóñez, Ana, Marcos-Ramiro, Beatriz, Aguilar-Garrido, Pedro, Cushman, Ian, Romero, Antonio, Medrano, Francisco J., Gajate, Consuelo, Mollinedo, Faustino, Philips, Mark R., Campillo, Mercedes, Gallardo, Miguel, Martín-Fontecha, Mar, López-Rodríguez, María L., Ortega-Gutiérrez, Silvia · 2019 · Journal of Medicinal Chemistry
Cited by 47

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Blockade of Ras activity by inhibiting its post-translational methylation catalyzed by isoprenylcysteine carboxylmethyltransferase (ICMT) has been suggested as a promising antitumor strategy. However, the paucity of inhibitors has precluded the clinical validation of this approach. In this work we report a potent ICMT inhibitor, compound 3 [UCM-1336, IC 50 = 2 μM], which is selective against the other enzymes involved in the post-translational modifications of Ras. Compound 3 significantly impairs the membrane association of the four Ras isoforms, leading to a decrease of Ras activity and to inhibition of Ras downstream signaling pathways. In addition, it induces cell death in a variety of Ras-mutated tumor cell lines and increases survival in an in vivo model of acute myeloid leukemia. Because ICMT inhibition impairs the activity of the four Ras isoforms regardless of its activating mutation, compound 3 surmounts many of the common limitations of available Ras inhibitors described so far. In addition, these results validate ICMT as a valuable target for the treatment of Ras-driven tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.9b00145

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 47

Metadata

Authors
Marín-Ramos, N. I., Balabasquer, M., Ortega-Nogales, F. J., Torrecillas, I. R., Gil-Ordóñez, A., Marcos-Ramiro, B., Aguilar-Garrido, P., Cushman, I., Romero, A., Medrano, F. J., Gajate, C., Mollinedo, F., Philips, M. R., Campillo, M., Gallardo, M., Martín-Fontecha, M., López-Rodríguez, M. L., & Ortega-Gutiérrez, S.
Venue
Journal of Medicinal Chemistry
Published
2019-06-10
Volume
62
Issue
13
Pages
6035-6046
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2950607674
Cited by
47
References
12
FWCI
1.93
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1021/acs.jmedchem.9b00145
The paper
Marín-Ramos, N. I., Balabasquer, M., Ortega-Nogales, F. J., Torrecillas, I. R., Gil-Ordóñez, A., Marcos-Ramiro, B., Aguilar-Garrido, P., Cushman, I., Romero, A., Medrano, F. J., Gajate, C., Mollinedo, F., Philips, M. R., Campillo, M., Gallardo, M., Martín-Fontecha, M., López-Rodríguez, M. L., & Ortega-Gutiérrez, S. (2019). A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.9b00145

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.